A phase I/IIa, open-label, multicentre study evaluating the safety, tolerability, and efficacy of RZ-001 in combination with valganciclovir (VGCV) in patients (pts) with human telomerase reverse transcriptase (hTERT)-positive glioblastoma multiforme (GBM)

Kong, D. S.; Yee, G. T.; Kim, C. Y.; Hong, C. K.; Yoon, W. S.; Kang, S. G.; Choi, J. W.; Hong, S.; Jeon, E.

doi:10.1016/j.annonc.2025.10.325

상세 보기

A phase I/IIa, open-label, multicentre study evaluating the safety, tolerability, and efficacy of RZ-001 in combination with valganciclovir (VGCV) in patients (pts) with human telomerase reverse transcriptase (hTERT)-positive glioblastoma multiforme (GBM)

Kong, D. S.;
Yee, G. T.;
Kim, C. Y.;
Hong, C. K.;
Yoon, W. S.;
... Choi, J. W.;
외 3명

Citations

WEB OF SCIENCE

0

제목: A phase I/IIa, open-label, multicentre study evaluating the safety, tolerability, and efficacy of RZ-001 in combination with valganciclovir (VGCV) in patients (pts) with human telomerase reverse transcriptase (hTERT)-positive glioblastoma multiforme (GBM)

저자: Kong, D. S.; Yee, G. T.; Kim, C. Y.; Hong, C. K.; Yoon, W. S.; Kang, S. G.; Choi, J. W.; Hong, S.; Jeon, E.

DOI: 10.1016/j.annonc.2025.10.325

발행일: 2025-12

유형: Meeting Abstract

저널명: Annals of Oncology

권: 36

ScholarWorks@성균관대학교

상세 보기